BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3091% above fair value
$57.23+0.53 (+0.93%)
Close on Nov 13, 2026Market cap $11.08BP/E 150.6Yield –
BioMarin Pharmaceutical EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
BioMarin Pharmaceutical's EV/EBITDA was 48.3× on Nov 11, 2026, against 13.3× a year earlier. Over the last 5 years it ranged from 10.3× to 542.7×, with a median of 49.4×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 48.3× | +34.1 |
| 2025 | Dec 31, 2025 | 14.2× | −11.5 |
| 2024 | Dec 31, 2024 | 25.8× | −43.0 |
| 2023 | Dec 29, 2023 | 68.8× | −16.0 |
| 2022 | Dec 30, 2022 | 84.9× | −280.5 |
| 2021 | Dec 31, 2021 | 365.4× | +224.8 |
| 2020 | Dec 31, 2020 | 140.6× | −81.1 |
| 2019 | Jan 31, 2019 | 221.6× | +32.0 |
| 2018 | Dec 31, 2018 | 189.6× | −17.2 |
| 2012 | Jan 31, 2012 | 206.8× | +7.7 |
| 2011 | Dec 30, 2011 | 199.0× | +130.1 |
| 2010 | Dec 31, 2010 | 68.9× | +38.8 |
| 2009 | Dec 31, 2009 | 30.1× | – |
See a number that looks wrong?